5,240 Shares in Incyte Co. (NASDAQ:INCY) Purchased by OLD Mission Capital LLC

OLD Mission Capital LLC bought a new stake in Incyte Co. (NASDAQ:INCY) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 5,240 shares of the biopharmaceutical company’s stock, valued at approximately $496,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Raymond James & Associates raised its stake in shares of Incyte by 14.1% during the fourth quarter. Raymond James & Associates now owns 29,020 shares of the biopharmaceutical company’s stock worth $2,748,000 after acquiring an additional 3,582 shares in the last quarter. Bridger Management LLC raised its stake in shares of Incyte by 97.3% during the fourth quarter. Bridger Management LLC now owns 622,152 shares of the biopharmaceutical company’s stock worth $58,924,000 after acquiring an additional 306,890 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of Incyte by 1.4% during the fourth quarter. California State Teachers Retirement System now owns 285,246 shares of the biopharmaceutical company’s stock worth $27,016,000 after acquiring an additional 3,962 shares in the last quarter. Two Sigma Investments LP raised its stake in shares of Incyte by 143.1% during the fourth quarter. Two Sigma Investments LP now owns 729,107 shares of the biopharmaceutical company’s stock worth $69,054,000 after acquiring an additional 429,181 shares in the last quarter. Finally, HealthCor Management L.P. raised its stake in shares of Incyte by 125.5% during the fourth quarter. HealthCor Management L.P. now owns 1,350,000 shares of the biopharmaceutical company’s stock worth $127,859,000 after acquiring an additional 751,450 shares in the last quarter. 93.50% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

In other news, EVP Reid M. Huber sold 1,958 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $85.55, for a total transaction of $167,506.90. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider David W. Gryska sold 1,952 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $85.56, for a total transaction of $167,013.12. Following the sale, the insider now owns 12,922 shares in the company, valued at approximately $1,105,606.32. The disclosure for this sale can be found here. Insiders own 17.20% of the company’s stock.

INCY has been the topic of several research reports. Nomura reissued a “buy” rating on shares of Incyte in a research note on Thursday, February 1st. Guggenheim reaffirmed a “neutral” rating on shares of Incyte in a research note on Friday. Raymond James Financial set a $159.00 target price on shares of Incyte and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Deutsche Bank initiated coverage on shares of Incyte in a research note on Tuesday, December 12th. They issued a “hold” rating and a $106.00 target price on the stock. Finally, Credit Suisse Group set a $145.00 target price on shares of Incyte and gave the stock a “buy” rating in a research note on Wednesday, February 14th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $131.03.

NASDAQ:INCY traded down $19.05 during trading hours on Friday, hitting $64.02. The company had a trading volume of 26,083,758 shares, compared to its average volume of 1,503,206. The stock has a market cap of $13,559.37, a P/E ratio of 100.03 and a beta of 0.66. Incyte Co. has a 52 week low of $63.43 and a 52 week high of $142.45. The company has a quick ratio of 3.99, a current ratio of 4.01 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.54. The business had revenue of $444.20 million for the quarter, compared to analysts’ expectations of $435.23 million. Incyte had a negative net margin of 20.38% and a negative return on equity of 11.85%. The firm’s revenue for the quarter was up 36.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.05 earnings per share. analysts expect that Incyte Co. will post -0.28 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “5,240 Shares in Incyte Co. (NASDAQ:INCY) Purchased by OLD Mission Capital LLC” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/08/old-mission-capital-llc-buys-shares-of-5240-incyte-co-incy.html.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply